Spotlight on Pediatrics
Improving the Delivery of Immunotherapy for Peanut Allergy Management – Rapid Response From Lisbon
StartActivity Details
Expires: August 6, 2020
Provider Statement
This continuing medical education activity is provided by
Support Statement
This activity is supported by an educational grant from Aimmune Therapeutics, Inc.
Activity Chair
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director, Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL
- Disclosures:
Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
Contracted Research: Thermo Fisher Scientific, United Health Group
Faculty
Associate Professor of Pediatric Allergy
Director, Food Immunotherapy Program
Associate Director, Food Allergy Program
Immunology, Allergy and Rheumatology
Texas Children's Hospital
Baylor College of Medicine
Houston, TX
- Disclosures:
Contracted Research (paid to institution): Aimmune
Associate Professor of Pediatrics
Section Chief
Allergy/Immunology and Pediatric Pulmonology and Sleep Medicine
University of Chicago Medicine
Chicago, IL
- Disclosures:
Consulting Fee: Aimmune, Regeneron
Speakers Bureau: Aimmune
Contracted Research: Aimmune, Astellas, DBV Technologies, Sanofi
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education staff report the following
relationship(s):
No relevant financial relationships to disclose.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, August 7, 2019 to August 6, 2020.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the video, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Overview
The prevalence of food allergy has been increasing, especially among children, with nearly 1 in 13 children in the United States being impacted. Peanut allergy, in particular, has attracted growing attention in recent years as it has become increasingly common. Despite this, there are no approved treatments specifically for food allergy, and standard immunotherapy has limitations. This CME activity will assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management and will feature the most recent data from the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.
Target Audience
The intended audience for the activity is allergists, immunologists, and other health care professionals involved in the management of patients with peanut allergy.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management.
- Review the potential impact of raising the peanut allergen threshold on patient quality of life and/or the need for emergent care.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: August 6, 2020
Provider Statement
This continuing medical education activity is provided by
Support Statement
This activity is supported by an educational grant from Aimmune Therapeutics, Inc.
Activity Chair
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director, Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL
- Disclosures:
Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
Contracted Research: Thermo Fisher Scientific, United Health Group
Faculty
Associate Professor of Pediatric Allergy
Director, Food Immunotherapy Program
Associate Director, Food Allergy Program
Immunology, Allergy and Rheumatology
Texas Children's Hospital
Baylor College of Medicine
Houston, TX
- Disclosures:
Contracted Research (paid to institution): Aimmune
Associate Professor of Pediatrics
Section Chief
Allergy/Immunology and Pediatric Pulmonology and Sleep Medicine
University of Chicago Medicine
Chicago, IL
- Disclosures:
Consulting Fee: Aimmune, Regeneron
Speakers Bureau: Aimmune
Contracted Research: Aimmune, Astellas, DBV Technologies, Sanofi
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education staff report the following
relationship(s):
No relevant financial relationships to disclose.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, August 7, 2019 to August 6, 2020.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the video, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Overview
The prevalence of food allergy has been increasing, especially among children, with nearly 1 in 13 children in the United States being impacted. Peanut allergy, in particular, has attracted growing attention in recent years as it has become increasingly common. Despite this, there are no approved treatments specifically for food allergy, and standard immunotherapy has limitations. This CME activity will assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management and will feature the most recent data from the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.
Target Audience
The intended audience for the activity is allergists, immunologists, and other health care professionals involved in the management of patients with peanut allergy.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management.
- Review the potential impact of raising the peanut allergen threshold on patient quality of life and/or the need for emergent care.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Pediatrics Presentations
Improving the Delivery of Immunotherapy for Peanut Allergy Management – Rapid Response From Lisbon
StartActivity Details
Expires: August 6, 2020
Provider Statement
This continuing medical education activity is provided by
Support Statement
This activity is supported by an educational grant from Aimmune Therapeutics, Inc.
Activity Chair
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director, Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL
- Disclosures:
Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
Contracted Research: Thermo Fisher Scientific, United Health Group
Faculty
Associate Professor of Pediatric Allergy
Director, Food Immunotherapy Program
Associate Director, Food Allergy Program
Immunology, Allergy and Rheumatology
Texas Children's Hospital
Baylor College of Medicine
Houston, TX
- Disclosures:
Contracted Research (paid to institution): Aimmune
Associate Professor of Pediatrics
Section Chief
Allergy/Immunology and Pediatric Pulmonology and Sleep Medicine
University of Chicago Medicine
Chicago, IL
- Disclosures:
Consulting Fee: Aimmune, Regeneron
Speakers Bureau: Aimmune
Contracted Research: Aimmune, Astellas, DBV Technologies, Sanofi
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education staff report the following
relationship(s):
No relevant financial relationships to disclose.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, August 7, 2019 to August 6, 2020.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the video, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Overview
The prevalence of food allergy has been increasing, especially among children, with nearly 1 in 13 children in the United States being impacted. Peanut allergy, in particular, has attracted growing attention in recent years as it has become increasingly common. Despite this, there are no approved treatments specifically for food allergy, and standard immunotherapy has limitations. This CME activity will assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management and will feature the most recent data from the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.
Target Audience
The intended audience for the activity is allergists, immunologists, and other health care professionals involved in the management of patients with peanut allergy.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management.
- Review the potential impact of raising the peanut allergen threshold on patient quality of life and/or the need for emergent care.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: August 6, 2020
Provider Statement
This continuing medical education activity is provided by
Support Statement
This activity is supported by an educational grant from Aimmune Therapeutics, Inc.
Activity Chair
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director, Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL
- Disclosures:
Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
Contracted Research: Thermo Fisher Scientific, United Health Group
Faculty
Associate Professor of Pediatric Allergy
Director, Food Immunotherapy Program
Associate Director, Food Allergy Program
Immunology, Allergy and Rheumatology
Texas Children's Hospital
Baylor College of Medicine
Houston, TX
- Disclosures:
Contracted Research (paid to institution): Aimmune
Associate Professor of Pediatrics
Section Chief
Allergy/Immunology and Pediatric Pulmonology and Sleep Medicine
University of Chicago Medicine
Chicago, IL
- Disclosures:
Consulting Fee: Aimmune, Regeneron
Speakers Bureau: Aimmune
Contracted Research: Aimmune, Astellas, DBV Technologies, Sanofi
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education staff report the following
relationship(s):
No relevant financial relationships to disclose.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, August 7, 2019 to August 6, 2020.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the video, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 67% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Overview
The prevalence of food allergy has been increasing, especially among children, with nearly 1 in 13 children in the United States being impacted. Peanut allergy, in particular, has attracted growing attention in recent years as it has become increasingly common. Despite this, there are no approved treatments specifically for food allergy, and standard immunotherapy has limitations. This CME activity will assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management and will feature the most recent data from the 2019 European Academy of Allergy and Clinical Immunology (EAACI) Congress.
Target Audience
The intended audience for the activity is allergists, immunologists, and other health care professionals involved in the management of patients with peanut allergy.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the latest clinical evidence regarding new or late-stage oral immunotherapy options for peanut allergy management.
- Review the potential impact of raising the peanut allergen threshold on patient quality of life and/or the need for emergent care.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Enhancing the Patient-Provider Connection: Practical Strategies for Improving Outcomes in Obesity Management
StartActivity Details
Expires: June 6, 2020
Provided By
Target Audience
This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Analyze regional and ethnic disparities in obesity
- Address patients with obesity with sensitivity and a greater understanding of this disorder’s causes, challenges, and treatments
- Apply current practice guidelines to optimize screening, diagnosis, and treatment
- Implement proven communication strategies, such as The 5 A’s of Obesity Counseling, to effectively engage patients in weight loss discussion
- Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss
Activity Description
The U.S. Preventative Services Task Force and the American Academy of Pediatrics recommend that physicians screen patients for obesity and practice counseling interventions to achieve modest (4%-8%) weight loss. Despite this, physicians frequently do not document obesity, counsel, or initiate therapy for weight loss. Medically-managed weight loss may provide the safest and most effective means to initial weight loss and weight loss maintenance over time. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of health professionals. This program will improve family physicians’ skills and confidence in weight loss counseling and treatment while also discussing geographic, ethnic, and racial disparities.
Statement of Educational Need
In this CME activity, you will view video clips of unhelpful and helpful clinicians and expert faculty commentary to learn how to effectively and appropriately screen, diagnose, and treat patients with obesity.
Faculty
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Deborah Bade Horn, DO, MPH
Consulting Fees: Bausch Health/Valeant Pharmaceuticals International; Novo
Nordisk, Inc.
Speakers’ Bureau: Novo Nordisk, Inc.
Contracted Research: Novo Nordisk, Inc.
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of June 6, 2019 through June 6, 2020 participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information for Questions About the Activity
For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from Novo Nordisk Inc.
Activity Details
Expires: June 6, 2020
Provided By
Target Audience
This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Analyze regional and ethnic disparities in obesity
- Address patients with obesity with sensitivity and a greater understanding of this disorder’s causes, challenges, and treatments
- Apply current practice guidelines to optimize screening, diagnosis, and treatment
- Implement proven communication strategies, such as The 5 A’s of Obesity Counseling, to effectively engage patients in weight loss discussion
- Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss
Activity Description
The U.S. Preventative Services Task Force and the American Academy of Pediatrics recommend that physicians screen patients for obesity and practice counseling interventions to achieve modest (4%-8%) weight loss. Despite this, physicians frequently do not document obesity, counsel, or initiate therapy for weight loss. Medically-managed weight loss may provide the safest and most effective means to initial weight loss and weight loss maintenance over time. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of health professionals. This program will improve family physicians’ skills and confidence in weight loss counseling and treatment while also discussing geographic, ethnic, and racial disparities.
Statement of Educational Need
In this CME activity, you will view video clips of unhelpful and helpful clinicians and expert faculty commentary to learn how to effectively and appropriately screen, diagnose, and treat patients with obesity.
Faculty
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Deborah Bade Horn, DO, MPH
Consulting Fees: Bausch Health/Valeant Pharmaceuticals International; Novo
Nordisk, Inc.
Speakers’ Bureau: Novo Nordisk, Inc.
Contracted Research: Novo Nordisk, Inc.
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of June 6, 2019 through June 6, 2020 participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information for Questions About the Activity
For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from Novo Nordisk Inc.
Chronic Idiopathic Urticaria: Improving Treatment, With a Focus on Patient Outcomes
StartActivity Details
Expires: April 17, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists and other health care professionals involved in the treatment of patients with chronic idiopathic urticaria (CIU).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the impact of chronic idiopathic urticaria (CIU) on quality of life, including sleep, psychological functioning, work and activity.
- Compare the strengths and limitations of current guideline approaches to the management of CIU.
- Select treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.
Activity Description
Urticaria, a common skin condition characterized by transient pruritic wheals, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration over 6 weeks may be diagnosed as having chronic idiopathic urticaria (CIU). CIU negatively impacts physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease awaiting bypass surgery. A US practice guideline issued in 2014 and an updated international guideline issued in 2018 are available to guide diagnosis and treatment of urticaria. Although the recommendations in these guidelines largely overlap, specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME activity will assess the impact of CIU on quality of life, particularly its impact on sleep, psychological functioning, work, and activity. Current guideline approaches to the management of CIU will be evaluated, as well as treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.
Activity Chair
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH
Disclosures
Royalty: CRC Press, Springer Publishing
Intellectual Property/Patent Details: University of Cincinnati
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire
Speakers Bureau: ALK, AstraZeneca, CSL Behring, Novartis, Optinose, Pharming, Sanofi, Shire
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire
Faculty
Professor of Medicine and Pediatrics
Allergy and Immunology Program Director
University of Texas Southwestern Medical Center
Dallas, TX
Disclosures
Royalty: Elsevier, UpToDate
Speakers Bureau: Genentech
Data Safety Monitoring Committee: Aimmune
Head of the Allergy Center Charité - Dermatology Clinic
Spokesman for the Comprehensive Allergy Center Charité
Allergy Center Charité
Charité - Universitätsmedizin Berlin
Berlin, Germany
Disclosures
Consulting Fee: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Speakers Bureau: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Committee Member: WHO-Initiative "Allergic Rhinitis and its Impact on Asthma" (ARIA)
Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI)
Head: European Centre for Allergy Research Foundation (ECARF)
Secretary General: Global Allergy and Asthma European Network (GA2LEN)
Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organisation (WAO)
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, April 18, 2019 to April 17, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentations, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Participation Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Contact Information for Questions about the Activity
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: April 17, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is allergists and other health care professionals involved in the treatment of patients with chronic idiopathic urticaria (CIU).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the impact of chronic idiopathic urticaria (CIU) on quality of life, including sleep, psychological functioning, work and activity.
- Compare the strengths and limitations of current guideline approaches to the management of CIU.
- Select treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.
Activity Description
Urticaria, a common skin condition characterized by transient pruritic wheals, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration over 6 weeks may be diagnosed as having chronic idiopathic urticaria (CIU). CIU negatively impacts physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease awaiting bypass surgery. A US practice guideline issued in 2014 and an updated international guideline issued in 2018 are available to guide diagnosis and treatment of urticaria. Although the recommendations in these guidelines largely overlap, specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME activity will assess the impact of CIU on quality of life, particularly its impact on sleep, psychological functioning, work, and activity. Current guideline approaches to the management of CIU will be evaluated, as well as treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.
Activity Chair
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH
Disclosures
Royalty: CRC Press, Springer Publishing
Intellectual Property/Patent Details: University of Cincinnati
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire
Speakers Bureau: ALK, AstraZeneca, CSL Behring, Novartis, Optinose, Pharming, Sanofi, Shire
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire
Faculty
Professor of Medicine and Pediatrics
Allergy and Immunology Program Director
University of Texas Southwestern Medical Center
Dallas, TX
Disclosures
Royalty: Elsevier, UpToDate
Speakers Bureau: Genentech
Data Safety Monitoring Committee: Aimmune
Head of the Allergy Center Charité - Dermatology Clinic
Spokesman for the Comprehensive Allergy Center Charité
Allergy Center Charité
Charité - Universitätsmedizin Berlin
Berlin, Germany
Disclosures
Consulting Fee: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Speakers Bureau: AbbVie, ALK, Almirall, Astellas, AstraZeneca, Bayer, Bencard, Berlin-Chemie, FAES, HAL Allergy, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB
Committee Member: WHO-Initiative "Allergic Rhinitis and its Impact on Asthma" (ARIA)
Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI)
Head: European Centre for Allergy Research Foundation (ECARF)
Secretary General: Global Allergy and Asthma European Network (GA2LEN)
Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organisation (WAO)
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, April 18, 2019 to April 17, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentations, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Participation Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Contact Information for Questions about the Activity
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
SMA Management: Data, Insights and Practice
StartActivity Details
Expires: December 6, 2019
Accredited By
Target Audience
Pediatric neurologists, neurologists, neuromuscular specialists, pediatricians
Learning Objectives
- Review new information on the management of patients with SMA released at the Child Neurology Society and World Muscle Society 2018 annual meetings
- Apply new information to current SMA management practices, as relevant
Activity Description
This education provides the opportunity to learn the latest in the management of patients with Type 1 or Type 3 spinal muscular atrophy (SMA). Abstracts of posters from recent neurology meetings are presented followed by video discussions by expert faculty regarding the implication on the management of patients. Skills can then be applied in an interactive case where the learner is challenged to make decisions for a patient with Type 1 or Type 3 SMA.
Statement of Educational Need
The recent, rapid influx of information surrounding approved and emerging treatments for spinal muscular atrophy (SMA) has created a gap in clinician knowledge and the ability to apply it to practice.
Agenda
Type 1 SMA abstracts
NURTURE Update in Presymptomatic Patients (3:35)
Dr. Nancy Kuntz and Dr. Richard Finkel
Improvement for Patients in ENDEAR Study (4:07)
Dr. Nancy Kuntz and Dr. Richard Finkel
Type 1 interactive case
Type 3 SMA abstracts
Results in Type 3 Patients Treated with Nusinersen (3:05)
Dr. Richard Finkel, Dr. Nancy Kuntz, and Dr. Gyula Acsadi
A Multidisciplinary Team is Essential to the Management of SMA
(2:08)
Dr. Thomas Crawford and Dr. Laurent Servais
Type 3 interactive case
Faculty
Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Farmington, Connecticut
- Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Sarepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Sarepta.
Thomas Crawford, MD
Co-Director, Muscular Dystrophy Association Clinic
Professor of Neurology
Johns Hopkins Medicine
Baltimore, Maryland
- Dr. Crawford serves as a consultant and is on the advisory boards for AveXis, Inc., Biogen, Mallinckrodt, Marathon, Roche/Genentech, Santhera, and Scholar Rock.
Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida
- Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Roche, and Novartis. He receives clinical trial support from AveXis, Biogen, Ionis, Catabasis, Cytokinetics, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.
Nancy L. Kuntz, MD
Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Attending Physician
Division of Neurology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois
- Dr. Kuntz serves on clinical advisory boards for Audentes, AveXis, Inc., Biogen, Roche, and Sarepta. She has participated in educational lectures funded by Biogen.
Laurent Servais, MD, PhD
Pediatric Neurology
Institut de Myologie
Paris, France
- Dr. Servais serves on advisory boards for AveXis, Inc., Biogen, and Roche. He is a principle investigator for projects funded by AveXis, Inc., Biogen, and Roche.
Conflict of Interest Policy/Disclosure Statement
Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, The France
Foundation (TFF) requires that individuals in a position to control the
content of an educational activity disclose all relevant financial
relationships with any commercial interest. TFF resolves all conflicts of
interest to ensure independence, objectivity, balance, and scientific rigor
in all its educational programs. Furthermore, TFF seeks to verify that all
scientific research referred to, reported, or used in a CME/CE activity
conforms to the generally accepted standards of experimental design, data
collection, and analysis. TFF is committed to providing learners with
high-quality CME/CE activities that promote improvements in health care and
not those of a commercial interest.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by an educational grant from Biogen.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Activity Details
Expires: December 6, 2019
Accredited By
Target Audience
Pediatric neurologists, neurologists, neuromuscular specialists, pediatricians
Learning Objectives
- Review new information on the management of patients with SMA released at the Child Neurology Society and World Muscle Society 2018 annual meetings
- Apply new information to current SMA management practices, as relevant
Activity Description
This education provides the opportunity to learn the latest in the management of patients with Type 1 or Type 3 spinal muscular atrophy (SMA). Abstracts of posters from recent neurology meetings are presented followed by video discussions by expert faculty regarding the implication on the management of patients. Skills can then be applied in an interactive case where the learner is challenged to make decisions for a patient with Type 1 or Type 3 SMA.
Statement of Educational Need
The recent, rapid influx of information surrounding approved and emerging treatments for spinal muscular atrophy (SMA) has created a gap in clinician knowledge and the ability to apply it to practice.
Agenda
Type 1 SMA abstracts
NURTURE Update in Presymptomatic Patients (3:35)
Dr. Nancy Kuntz and Dr. Richard Finkel
Improvement for Patients in ENDEAR Study (4:07)
Dr. Nancy Kuntz and Dr. Richard Finkel
Type 1 interactive case
Type 3 SMA abstracts
Results in Type 3 Patients Treated with Nusinersen (3:05)
Dr. Richard Finkel, Dr. Nancy Kuntz, and Dr. Gyula Acsadi
A Multidisciplinary Team is Essential to the Management of SMA
(2:08)
Dr. Thomas Crawford and Dr. Laurent Servais
Type 3 interactive case
Faculty
Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Farmington, Connecticut
- Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Sarepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Sarepta.
Thomas Crawford, MD
Co-Director, Muscular Dystrophy Association Clinic
Professor of Neurology
Johns Hopkins Medicine
Baltimore, Maryland
- Dr. Crawford serves as a consultant and is on the advisory boards for AveXis, Inc., Biogen, Mallinckrodt, Marathon, Roche/Genentech, Santhera, and Scholar Rock.
Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida
- Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Roche, and Novartis. He receives clinical trial support from AveXis, Biogen, Ionis, Catabasis, Cytokinetics, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.
Nancy L. Kuntz, MD
Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Attending Physician
Division of Neurology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois
- Dr. Kuntz serves on clinical advisory boards for Audentes, AveXis, Inc., Biogen, Roche, and Sarepta. She has participated in educational lectures funded by Biogen.
Laurent Servais, MD, PhD
Pediatric Neurology
Institut de Myologie
Paris, France
- Dr. Servais serves on advisory boards for AveXis, Inc., Biogen, and Roche. He is a principle investigator for projects funded by AveXis, Inc., Biogen, and Roche.
Conflict of Interest Policy/Disclosure Statement
Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, The France
Foundation (TFF) requires that individuals in a position to control the
content of an educational activity disclose all relevant financial
relationships with any commercial interest. TFF resolves all conflicts of
interest to ensure independence, objectivity, balance, and scientific rigor
in all its educational programs. Furthermore, TFF seeks to verify that all
scientific research referred to, reported, or used in a CME/CE activity
conforms to the generally accepted standards of experimental design, data
collection, and analysis. TFF is committed to providing learners with
high-quality CME/CE activities that promote improvements in health care and
not those of a commercial interest.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by an educational grant from Biogen.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Evolving Management Strategies for Moderate-to-Severe Atopic Dermatitis: Looking Beyond Barriers to Optimize Therapy
StartExpires: December 13, 2019
This activity is supported by an educational grant from Sanofi Genzyme and
Regeneron Pharmaceuticals.
This activity is jointly provided by Global Education Group and Integritas
Communications.
Target Audience
The educational design of this activity addresses the needs of dermatologists, allergists, and other clinicians who treat patients with atopic dermatitis.
Statement of Need
Atopic dermatitis is a common, chronic inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.1,2 The disease-related physical and biopsychosocial burdens of atopic dermatitis can have a substantial effect on patients’ quality of life, particularly in those with moderate-to-severe disease.3,4 A better understanding of atopic dermatitis etiology has supported the development of new approaches to disease characterization and targeted therapies.5,6 As a result, the first biologic therapy is now available to treat patients with moderate-to-severe disease, and several other therapies are in late-stage clinical development.7-10 With novel therapies emerging for patients with difficult-to-treat atopic dermatitis, dermatologists will benefit from updates on the latest clinical trial data and practical recommendations on how to translate those results into daily clinical decision-making. In this Evidence-Based Best Practices™ program, internationally recognized experts will review the latest published evidence with a goal of providing recommendations to enhance overall patient outcomes. The expert faculty panel will discuss the pathophysiologic underpinnings of atopic dermatitis, share best practices related to comprehensive patient evaluations, and relay their own clinical experience in managing patients with moderate-to-severe disease.
References
- Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16.
- Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
- Whiteley J, et al. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1-7. [Epub ahead of print].
- Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
- Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
- Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
- Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
- de Bruin-Weller M, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083-1101.
- Boguniewicz M. Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract. 2017;5(6):1477-1487.
- Cotter DG, et al. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3S1):S53-S62.
Educational Objectives
After completing this activity, the participant should be better able to:
- Discuss atopic dermatitis pathophysiology, including clinically relevant molecular and cellular targets
- Assess patients with atopic dermatitis longitudinally for uncontrolled symptoms, disease flares, comorbidities, and clinical responses to their current treatment regimens
- Describe the clinical profiles of targeted biologic therapies for the treatment of moderate-to-severe atopic dermatitis
- Optimize treatment regimens for patients with moderate-to-severe atopic dermatitis to reduce symptomatology, address comorbidities, maximize health-related quality of life, and minimize treatment-related side effects
- Educate patients and caregivers to improve their understanding of atopic dermatitis to promote shared decision-making and treatment adherence
Faculty
Head, National Expertise Center for Atopic Dermatitis
Department of Dermatology/Allergology
University Medical Center Utrecht
Utrecht, The Netherlands
Professor of Dermatology
Director, Clinical Research
Department of Dermatology
Oregon Health & Science University
Portland, Oregon, USA
Professor
Department of Dermatology and Allergy
Ludwig-Maximilian University of Munich
Munich, Germany
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must score 70% on the posttest and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Marjolein de Bruin-Weller, MD, PhD
- Consultant/Advisor: AbbVie Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
- Grant/Research Support: Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.
Eric L. Simpson, MD, MCR
- Consultant/Advisor: AbbVie Inc., Eli Lilly and Company, Galderma Laboratories, L.P., LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.
- Grant/Research Support: Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Vanda Pharmaceuticals Inc.
Andreas Wollenberg, MD, PhD
- Consultant/Advisor: Almirall Limited, Beiersdorf AG, Galderma S.A., LEO Pharma Inc., L’Oréal S.A., MedImmune, LLC, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.
- Grant/Research Support: Beiersdorf AG, LEO Pharma Inc.
- Speakers Bureau: Almirall Limited, Anacor Pharmaceuticals, Inc., Astellas Pharma Europe Ltd, Beierdsorf AG, Bioderma Laboratoire Dermatologique, Celgene Corporation, Chugai Pharmaceutical Co., Ltd., Galderma S.A., Hans Karrer GMBH, LEO Pharma Inc., L’Oréal S.A., Meda AB, MedImmune, LLC, Merck Sharp & Dohme Corp., Novartis Pharma AG, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Stacey Ullman, MHS
Nothing to disclose
Ashley Marostica, RN, MSN
Nothing to disclose
Lindsay Borvansky
Nothing to disclose
Andrea Funk
Nothing to disclose
Liddy Knight
Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Expires: December 13, 2019
This activity is supported by an educational grant from Sanofi Genzyme and
Regeneron Pharmaceuticals.
This activity is jointly provided by Global Education Group and Integritas
Communications.
Target Audience
The educational design of this activity addresses the needs of dermatologists, allergists, and other clinicians who treat patients with atopic dermatitis.
Statement of Need
Atopic dermatitis is a common, chronic inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.1,2 The disease-related physical and biopsychosocial burdens of atopic dermatitis can have a substantial effect on patients’ quality of life, particularly in those with moderate-to-severe disease.3,4 A better understanding of atopic dermatitis etiology has supported the development of new approaches to disease characterization and targeted therapies.5,6 As a result, the first biologic therapy is now available to treat patients with moderate-to-severe disease, and several other therapies are in late-stage clinical development.7-10 With novel therapies emerging for patients with difficult-to-treat atopic dermatitis, dermatologists will benefit from updates on the latest clinical trial data and practical recommendations on how to translate those results into daily clinical decision-making. In this Evidence-Based Best Practices™ program, internationally recognized experts will review the latest published evidence with a goal of providing recommendations to enhance overall patient outcomes. The expert faculty panel will discuss the pathophysiologic underpinnings of atopic dermatitis, share best practices related to comprehensive patient evaluations, and relay their own clinical experience in managing patients with moderate-to-severe disease.
References
- Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16.
- Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
- Whiteley J, et al. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1-7. [Epub ahead of print].
- Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
- Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
- Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
- Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
- de Bruin-Weller M, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083-1101.
- Boguniewicz M. Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract. 2017;5(6):1477-1487.
- Cotter DG, et al. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3S1):S53-S62.
Educational Objectives
After completing this activity, the participant should be better able to:
- Discuss atopic dermatitis pathophysiology, including clinically relevant molecular and cellular targets
- Assess patients with atopic dermatitis longitudinally for uncontrolled symptoms, disease flares, comorbidities, and clinical responses to their current treatment regimens
- Describe the clinical profiles of targeted biologic therapies for the treatment of moderate-to-severe atopic dermatitis
- Optimize treatment regimens for patients with moderate-to-severe atopic dermatitis to reduce symptomatology, address comorbidities, maximize health-related quality of life, and minimize treatment-related side effects
- Educate patients and caregivers to improve their understanding of atopic dermatitis to promote shared decision-making and treatment adherence
Faculty
Head, National Expertise Center for Atopic Dermatitis
Department of Dermatology/Allergology
University Medical Center Utrecht
Utrecht, The Netherlands
Professor of Dermatology
Director, Clinical Research
Department of Dermatology
Oregon Health & Science University
Portland, Oregon, USA
Professor
Department of Dermatology and Allergy
Ludwig-Maximilian University of Munich
Munich, Germany
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must score 70% on the posttest and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Marjolein de Bruin-Weller, MD, PhD
- Consultant/Advisor: AbbVie Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
- Grant/Research Support: Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.
Eric L. Simpson, MD, MCR
- Consultant/Advisor: AbbVie Inc., Eli Lilly and Company, Galderma Laboratories, L.P., LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.
- Grant/Research Support: Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Vanda Pharmaceuticals Inc.
Andreas Wollenberg, MD, PhD
- Consultant/Advisor: Almirall Limited, Beiersdorf AG, Galderma S.A., LEO Pharma Inc., L’Oréal S.A., MedImmune, LLC, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.
- Grant/Research Support: Beiersdorf AG, LEO Pharma Inc.
- Speakers Bureau: Almirall Limited, Anacor Pharmaceuticals, Inc., Astellas Pharma Europe Ltd, Beierdsorf AG, Bioderma Laboratoire Dermatologique, Celgene Corporation, Chugai Pharmaceutical Co., Ltd., Galderma S.A., Hans Karrer GMBH, LEO Pharma Inc., L’Oréal S.A., Meda AB, MedImmune, LLC, Merck Sharp & Dohme Corp., Novartis Pharma AG, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Stacey Ullman, MHS
Nothing to disclose
Ashley Marostica, RN, MSN
Nothing to disclose
Lindsay Borvansky
Nothing to disclose
Andrea Funk
Nothing to disclose
Liddy Knight
Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Advances in the Treatment of Peanut Allergy: Rapid Response from Seattle
StartActivity Details
Expires: November 30, 2019
Accredited By
This continuing medical education activity is provided by Vindico Medical
Education.
Faculty
Activity Chair:
Associate Professor of Pediatrics
Division of Allergy and Immunology
University of Texas Southwestern Medical Center
Director, Food Allergy Center
Children’s Medical Center of Dallas
Dallas, TX
Disclosure: Consulting Fee: Aimmune, DBV Technologies, Pharm-Olam
Non-CME Services Fees: Aimmune, DBV Technologies
Contracted Research: Aimmune, DBV Technologies
Faculty:
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director
Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL
Disclosure: Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
Contracted Research: Thermo Fisher Scientific, United Health Group
Director, UNC Food Allergy Initiative
University of North Carolina at Chapel Hill
Chapel Hill, NC
Disclosure: Consulting Fee: Aimmune, DBV Technologies
Contracted Research: Aimmune, Astellas, DBV Technologies, FARE, HAL Allergy
Research Support: Wallace Foundation
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Activity Description
The prevalence of peanut allergy in adults and children continues to increase, significantly disrupting the lives of the millions of affected individuals as well as their families. Although no therapies have been approved for the treatment of peanut allergies, several are currently being evaluated in clinical studies, providing the potential for safe and effective therapeutic options. Within this Rapid Response from Seattle, experts in the field examine the prevalence and burden of IgE-mediated food allergy with a focus on peanut allergy, assess the latest clinical data regarding the use of oral immunotherapy for the treatment of patients with peanut allergy, and evaluate the challenges associated with heterogeneity in terminology used in immunotherapy clinical trials for the management of patients with peanut allergy.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Examine the prevalence and burden of IgE-mediated food allergy, with a focus on peanut allergy.
- Assess the latest clinical data regarding the use of oral immunotherapy for the treatment of patients with peanut allergy.
- Examine the challenges associated with heterogeneity in terminology used in immunotherapy clinical trials for the management of patients with peanut allergy.
Target Audience
The intended audience for the activity is allergists, immunologists and other health care professionals involved in the treatment of patients with food allergies, particularly peanut allergy.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s) Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Aimmune Therapeutics.
Disclaimer Statement/Disclosure of Unlabeled Use
The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Contact Information for Questions About the Activity
Contact us at CME@VindicoCME.com
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Activity Details
Expires: November 30, 2019
Accredited By
This continuing medical education activity is provided by Vindico Medical
Education.
Faculty
Activity Chair:
Associate Professor of Pediatrics
Division of Allergy and Immunology
University of Texas Southwestern Medical Center
Director, Food Allergy Center
Children’s Medical Center of Dallas
Dallas, TX
Disclosure: Consulting Fee: Aimmune, DBV Technologies, Pharm-Olam
Non-CME Services Fees: Aimmune, DBV Technologies
Contracted Research: Aimmune, DBV Technologies
Faculty:
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director
Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL
Disclosure: Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
Contracted Research: Thermo Fisher Scientific, United Health Group
Director, UNC Food Allergy Initiative
University of North Carolina at Chapel Hill
Chapel Hill, NC
Disclosure: Consulting Fee: Aimmune, DBV Technologies
Contracted Research: Aimmune, Astellas, DBV Technologies, FARE, HAL Allergy
Research Support: Wallace Foundation
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Activity Description
The prevalence of peanut allergy in adults and children continues to increase, significantly disrupting the lives of the millions of affected individuals as well as their families. Although no therapies have been approved for the treatment of peanut allergies, several are currently being evaluated in clinical studies, providing the potential for safe and effective therapeutic options. Within this Rapid Response from Seattle, experts in the field examine the prevalence and burden of IgE-mediated food allergy with a focus on peanut allergy, assess the latest clinical data regarding the use of oral immunotherapy for the treatment of patients with peanut allergy, and evaluate the challenges associated with heterogeneity in terminology used in immunotherapy clinical trials for the management of patients with peanut allergy.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Examine the prevalence and burden of IgE-mediated food allergy, with a focus on peanut allergy.
- Assess the latest clinical data regarding the use of oral immunotherapy for the treatment of patients with peanut allergy.
- Examine the challenges associated with heterogeneity in terminology used in immunotherapy clinical trials for the management of patients with peanut allergy.
Target Audience
The intended audience for the activity is allergists, immunologists and other health care professionals involved in the treatment of patients with food allergies, particularly peanut allergy.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s) Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Aimmune Therapeutics.
Disclaimer Statement/Disclosure of Unlabeled Use
The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Contact Information for Questions About the Activity
Contact us at CME@VindicoCME.com
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection
StartActivity Details
Expires: November 20, 2019
Provided by
Integrity Continuing Education, Inc.
Target Audience
This educational initiative has been designed for allergists, pulmonologists, and otolaryngic allergists involved in the management of patients with severe asthma.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Describe clinical criteria for severe asthma and outline an approach to assessing symptom control and disease burden
- Identify known phenotypes of severe asthma
- Develop an approach to the treatment of severe asthma that is personalized to the individual patient and describe the most recent clinical data on new and emerging therapies for severe asthma
- Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma
Activity Description
Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this initiative is also targeted at providing clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.
Faculty
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
School of Medicine and Public Health
University of Wisconsin
Madison, Wisconsin
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
William W. Busse, MD
Royalty: Elsevier
Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech, GlaxoSmithKline,
Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron
Pharmaceuticals, Teva Pharmaceuticals
Data Monitoring Boards/Study Oversight Committees: Boston Scientific,
Genentech, ICON Clinical Research Ltd.
The Integrity CE planners and managers have nothing to disclose.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of November 20, 2018 through November 20, 2019 participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information for Questions About the Activity
For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Activity Details
Expires: November 20, 2019
Provided by
Integrity Continuing Education, Inc.
Target Audience
This educational initiative has been designed for allergists, pulmonologists, and otolaryngic allergists involved in the management of patients with severe asthma.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Describe clinical criteria for severe asthma and outline an approach to assessing symptom control and disease burden
- Identify known phenotypes of severe asthma
- Develop an approach to the treatment of severe asthma that is personalized to the individual patient and describe the most recent clinical data on new and emerging therapies for severe asthma
- Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma
Activity Description
Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this initiative is also targeted at providing clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.
Faculty
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
School of Medicine and Public Health
University of Wisconsin
Madison, Wisconsin
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
William W. Busse, MD
Royalty: Elsevier
Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech, GlaxoSmithKline,
Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron
Pharmaceuticals, Teva Pharmaceuticals
Data Monitoring Boards/Study Oversight Committees: Boston Scientific,
Genentech, ICON Clinical Research Ltd.
The Integrity CE planners and managers have nothing to disclose.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of November 20, 2018 through November 20, 2019 participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information for Questions About the Activity
For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.